Company intelligence / Profile preview

Blacktrace Holdings

Royston, England, United Kingdom

Ownership: Private
Employees: ~23
Development stage: Other

Overview

Blacktrace is a commercial-stage technology company that manufactures scientific products and platforms rather than developing clinical drugs. The company's technologies enable drug encapsulation, nanoparticle production, and single-cell analysis for use by customers in pharmaceutical, biotech, and medical device development.

Therapeutic areas: ImmunologyOtherEndocrinologyInfectious DiseasesOncology
Modalities: Microfluidic systemsNanoparticle delivery systems
Industry: Non-Drug Biotech

Partnerships

ReproCELL (partnership for Nadia series single-cell analysis system sales in Japan as of March 2021)

Beyond the preview

Go deeper on Blacktrace Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blacktrace Holdings.

Explore the full profile